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Clinical evidence regarding combination anticoagulant–
antiplatelet therapy has largely focused on atrial fibrillation
(AF) as the primary indication for anticoagulation. Expert
recommendations from the American College of Cardiology
(ACC) discourage the use of so-called ‘triple therapy’, that
is, anticoagulation and dual antiplatelet therapy (aspirin
and a P2Y12 inhibitor), in patients on preexisting antiplatelet therapy who develop a new venous thromboembolism
(VTE).1 However, this guidance is extrapolated from evidence in AF without robust data in the VTE population,
which has distinct demographics, comorbidities, and timevarying risk of recurrent thrombosis.2 To address this gap,
we explored a multicenter cohort of patients initiated on
warfarin therapy for management of VTE. Our study aimed
to evaluate the frequency and outcomes of antiplatelet therapy in addition to warfarin for patients with VTE.
We retrospectively analyzed adult patients in the Blue
Cross Blue Shield-sponsored Michigan Anticoagulation
Quality Improvement Initiative (MAQI2) registry who were
newly initiated on warfarin therapy for VTE and entered in
the registry between April 1, 2010 and October 31, 2020.3,4
Patients with a history of atrial fibrillation/flutter, heart
valve replacement, and/or antiphospholipid antibody syndrome were excluded. Patient data were abstracted from the
time of enrollment through the earliest of either the first
adverse event, discontinuation of warfarin, or last followup before October 31, 2020. Patient characteristics were
assessed at enrollment, while adverse events were assessed
at each follow-up visit. Adjusted associations between
number of antiplatelets and event outcomes were examined
using Cox proportional hazards.
Of the 2918 patients initiating warfarin for treatment of
VTE, 1333 (45.7%) were men with a mean (SD) age of
61.0 (16.4) years. During the study period, 820 patients
(28.1%) received warfarin plus one or more antiplatelet
medications, compared to 2098 (71.9%) who received

warfarin monotherapy (online Supplementary Table 1).
Patients on combination warfarin and antiplatelet therapy
had a higher incidence of documented coronary artery disease, prior myocardial infarction, and coronary revascularization. Compared to the warfarin monotherapy group, the
combination warfarin–antiplatelet group had a higher average RIETE bleed score (2.5 vs 2.0, p < 0.001).5,6 Aspirin
monotherapy was the most common antiplatelet regimen
(83.4%), followed by dual antiplatelet therapy (11.0%) and
P2Y12 inhibitor monotherapy (5.1%).
The warfarin monotherapy reference group experienced
3.3 thrombotic events per 100-patient-years, compared to
warfarin plus single antiplatelet (2.7 per 100-patient-years,
p = 0.190) or warfarin plus dual antiplatelet (2.2 per
100-patient-years, p = 0.773; Figure 1). The warfarin monotherapy reference group experienced 20.0 overall bleeding
events per 100-patient-years, compared to warfarin plus
single antiplatelet (24.7 per 100-patient-years, p = 0.013)
or warfarin plus dual antiplatelet (58.9 per 100-patientyears, p < 0.001; Figure 1).
After controlling for age, gender, race, provoked status
of VTE, and RIETE score, use of one antiplatelet
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Figure 1. Rates of thrombotic, bleeding, and associated events in patients with VTE with no, one, or two antiplatelet medications
in addition to warfarin.

A Poisson test was used to calculate p-values, in comparison to the warfarin monotherapy reference group; ‘ns’ denotes p > 0.05, *p < 0.05, **p <
0.01, ***p < 0.001.
ER, emergency room; FFP, fresh frozen plasma; ISTH, International Society on Thrombosis and Haemostasis; RBC, red blood cell; VTE, venous
thromboembolism.

medication (hazard ratio (HR) 1.21; 95% CI, 1.02–1.43)
and use of two antiplatelet medications (HR 2.37; 95% CI,
1.65–3.39) were associated with increased overall bleeding. When examining major bleeding as defined by the
International Society on Thrombosis and Haemostasis as
the outcome variable,7 use of one antiplatelet medication
(HR 1.37; 95% CI, 0.93–2.02) and use of two antiplatelet
medications (HR 1.58; 95% CI, 0.57–4.36) were not significant. With regards to nonmajor bleeding, use of one
antiplatelet medication (HR 1.20; 95% CI, 0.99–1.45) was
not significant whereas use of two antiplatelet medications
was significant (HR 2.53; 95% CI, 1.71–3.75).
In this large, registry-based cohort study of patients followed by anticoagulation clinics while receiving warfarin
for VTE, 28.1% of patients received either one or two additional antiplatelet medications. Compared to warfarin monotherapy, combination warfarin–antiplatelet therapy in
patients with VTE was associated with increased bleeding
and similar rates of thrombosis. This differential bleeding
risk is largely driven by nonmajor bleeds.
Our investigation is one of a few dedicated VTE studies
examining antithrombotic management in an unselected,
practice-based setting. These results provide additional evidence to support the recent 2021 ACC guidelines discouraging ‘triple therapy’ regimens in patients with VTE and
atherosclerotic cardiovascular disease, due to unnecessary
bleeding risk.1 Moreover, antiplatelet therapy has been
identified as one of the few potentially modifiable bleeding
risk factors in patients with VTE.6 Our findings are also
consistent with research demonstrating a significantly
higher rate of nonmajor bleeding, in particular among
patients taking combination aspirin–direct oral anticoagulant (DOAC) therapy compared to DOAC monotherapy.8
Limitations of this study include those inherent to registry
data, including the potential for unmeasured confounding.
It is unknown how these findings generalize to patients

receiving DOACs, though these results are consistent with a
meta-analysis of six randomized trials that demonstrated an
increased risk of bleeding and similar risk of thrombosis in
patients with VTE treated with combination DOAC–
antiplatelet therapy.9
In conclusion, use of combination anticoagulant–antiplatelet therapy among patients with VTE is common and
associated with higher risk of bleeding. Prospective studies
to validate the safety and efficacy of antiplatelet reduction
for patients receiving anticoagulation for VTE would
strengthen expert management recommendations.
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